

## Special Issue

# Real-World Clinical Studies in Acute Leukemia

### Message from the Guest Editor

Real-world clinical studies on acute leukemias are important because they provide valuable insights into treatment options and disease outcomes. These studies also allow us to evaluate the tolerability and efficacy of new and rapidly approved drugs in a real-life context among unselected patient populations, unlike those included in phase III clinical trials with selective criteria. This Special Issue, titled "Real-World Clinical Studies in Acute Leukemia", aims to collect multicentric, real-life experiences with new and emerging treatment options, such as hypomethylating agent combinations, venetoclax combinations, other targeted therapies, minimal residual disease (MRD)-driven treatments, post-stem cell transplant (SCT) maintenance or salvage therapy, in acute myeloid or lymphoid leukemia in both first-line and relapsed/refractory settings.

### Guest Editor

Prof. Dr. Anna Candoni

Section of Haematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, 41123 Modena, Italy

### Deadline for manuscript submissions

31 March 2026



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/243562](https://mdpi.com/si/243562)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)